arrow
V

Vanessa Roldán

Hospital Clínico Universitario Virgen de la Arrixaca
H指数:50
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort

应激性高血糖比率与接受抗凝治疗的房颤患者残余风险的关系:来自前瞻性穆尔西亚房颤项目III队列的报告

2025-12-010
OAAI
Perioperative and periprocedural management of antithrombotic therapy: 2025 consensus document of SEC, SEDAR, SEACV, SECCE, AEC, SECOM CYC, SECPRE, SEPD, SEGG, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEN, SEN, SENEC, SEPAR, SEO, SEORL-CCC, SEPA, SERVEI, SECOT, and AEU

抗血栓治疗的围手术期及围操作期管理:SEC、SEDAR、SEACV、SECCE、AEC、SECOM CYC、SECPRE、SEPD、SEGG、SEGO、SEHH、SETH、SEMERGEN、SEMFC、SEMG、SEMICYUC、SEMI、SEMES、SEN、SENEC、SEPAR、SEO、SEORL-CCC、SEPA、SERVEI、SECOT和AEU 2025年共识文件

2025-12-010
PRE
Relation of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio to residual risk in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF Project III cohort

非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比率与抗凝治疗房颤患者残余风险的关系:来自前瞻性穆尔西亚AF项目III队列的报告

2025-10-020
OAAI
A comparative analysis of HAS-BLED, ORBIT, DOAC and AF-BLEED bleeding risk scores in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III (MAFP-III) cohort

心房颤动抗凝患者HAS-BLED、ORBIT、DOAC和AF-BLEED出血风险评分的对比分析:来自前瞻性穆尔西亚心房颤动项目III(MAFP-III)队列的报告

2025-08-200
PRE
Frailty increases the risk of hospitalization for atrial fibrillation in older adults: a population-based cohort study

虚弱会增加老年人心房颤动住院的风险:一项基于人群的队列研究

2025-05-190
OAAI
Impact of Bone Marrow Evaluation Using Bone Marrow Biopsy, Flow Cytometry, and PET/CT in B-Cell Non-Hodgkin Lymphomas

骨髓评估对B细胞非霍奇金淋巴瘤的影响:使用骨髓活检、流式细胞术和PET/CT

BLOOD
IF23.1
2024-11-050
PRE
Patients with atrial fibrillation and common exclusion criteria from clinical trials are at high risk of clinical events: the Murcia AF Project II (MAFP-II) cohort study

临床试验中常见排除标准的房颤患者临床事件风险高: Murcia AF项目II (MAFP-II) 队列研究

2024-07-040
OAAI
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

预测利伐沙班治疗的房颤患者的血型出血和眼眶出血风险评分的性能: 来自EMIR前瞻性注册的观察结果

2022-11-019
PRE
Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

评估和减轻心房颤动和静脉血栓栓塞的出血风险: 欧洲和亚太地区专家共识文件的执行摘要

2022-07-0667
OA